1. Heus, K. G. C. B. B. et al. An overview of health issues and development in a large clinical cohort of children with Angelman syndrome. Am J Med Genet A 182, 53–63 (2020).
2. Besten, I. et al. Clinical aspects of a large group of adults with Angelman syndrome. Am J Med Genet A 185, 168–181 (2021).
3. 3. Avagliano-Trezza, R. A. et al. Loss of nuclear UBE3A causes electrophysiological and behavioral deficits in mice and is associated with Angelman syndrome. Nat Neurosci 22, 1235–1247 (2019).
4. Meng, L. et al. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 518, 409–412 (2015).
5. Silva-Santos S et al. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. J Clin Invest 125:2069–2076 (2015)
6. Milazzo, C. et al. Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model. J Clin Invest Insight 6, (2021).